BELLUS Health Inc
TSX:BLU
Net Margin
BELLUS Health Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
|
BELLUS Health Inc
TSX:BLU
|
2.5B CAD |
-578 587%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.8B USD |
6%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
159.9B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
148.6B USD |
22%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.8B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
106.9B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63B USD |
31%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
60.8B USD |
-13%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
BELLUS Health Inc
Glance View
BELLUS Health Inc., a biopharmaceutical company headquartered in Laval, Canada, has carved a niche for itself within the competitive landscape of drug development by focusing on addressing unmet medical needs, particularly within the domain of chronic cough. Its flagship product, BLU-5937, is a novel treatment under development intended to provide relief for millions of patients suffering from chronic refractory cough—a condition often overlooked by traditional pharmaceutical giants. The potential value of this compound lies in its unique mechanism as a P2X3 antagonist, which is designed to specifically target and alleviate cough symptoms without compromising the patient's sense of taste, a common side effect seen in previous attempts by other companies targeting the same receptor. The firm's strategic pathway to profitability revolves around the clinical success and eventual commercialization of BLU-5937. BELLUS Health has invested heavily in clinical trials to establish the compound’s efficacy and safety, navigating through the stringent phases mandated by health regulatory bodies such as the FDA. By achieving favorable trial results, the company positions itself advantageously for partnerships or acquisitions, often considered lucrative exits or expansion opportunities within the biotech industry. Revenue generation, at this juncture, primarily hinges on these strategic partnerships, where the promise of innovative, less invasive treatment alternatives to unmet health needs can potentially lead to substantial future royalties, milestone payments, and licensing deals, ensuring a lucrative return for BELLUS and its stakeholders.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on BELLUS Health Inc's most recent financial statements, the company has Net Margin of -578 586.7%.
You don't have any saved screeners yet